[Pulsatile treatment with gonadotropin-releasing hormone (GnRH)]
- PMID: 2274018
[Pulsatile treatment with gonadotropin-releasing hormone (GnRH)]
Abstract
The different ways of administration condition the frequency of the pulsatile GnRH, because of the different rate of depot. High frequencies (60-90/min) can be reached only with the intravenous route which is suitable for ovulation induction: ovulation is reached in 73-92% of women affected by hypothalamic amenorrhoea and in 41-51% of women affected by polycystic ovarian syndrome (previously suppressed with buserelin); overstimulation risk is lesser than during therapy with gonadotropins. Subcutaneous route is suitable for puberty induction which needs long-term treatment (18-24 months); the results are generally good, except in hypopituitaric patients. Intranasally route needs frequencies greater than 150-180 min: low frequencies administration (3 times/day) is sufficient to treat cryptorchidism and to reach good results (30-70%); moreover intranasally route can be useful to maintain the results reached with long term therapy with LHRH or gonadotropins.
Similar articles
-
Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH.Obstet Gynecol. 1996 Aug;88(2):221-6. doi: 10.1016/0029-7844(96)00190-1. Obstet Gynecol. 1996. PMID: 8692506 Clinical Trial.
-
Pulsatile GnRH therapy for the induction of ovulation in hypogonadotropic hypogonadism.Acta Endocrinol Suppl (Copenh). 1988;288:58-65. Acta Endocrinol Suppl (Copenh). 1988. PMID: 3138867
-
LHRH treatment of hypothalamic amenorrhoea.Acta Med Hung. 1986;43(2):223-8. Acta Med Hung. 1986. PMID: 3295744
-
Therapeutic uses of gonadotropin-releasing hormone analogs.Obstet Gynecol Surv. 1987 Jan;42(1):1-21. Obstet Gynecol Surv. 1987. PMID: 3543765 Review.
-
[Induction of ovulation by pulsatile gonadoliberin administration. Indications and limits].Ann Endocrinol (Paris). 1991;52(2):97-103. Ann Endocrinol (Paris). 1991. PMID: 1929195 Review. French.
Cited by
-
Update on cryptorchidism: endocrine, environmental and therapeutic aspects.J Endocrinol Invest. 2003 Jun;26(6):575-87. doi: 10.1007/BF03345224. J Endocrinol Invest. 2003. PMID: 12952375 Review.